Elanco Animal Health Incorporated

NYSE:ELAN

Drug Manufacturers - Specialty & Generic

Healthcare
$26.70 -3.47%

-$0.84 today

Market cap
$13.35B
Beta
1.70
P/E (TTM)
-48.1
EPS (TTM)
-$0.49
52W Low $13.16High $27.72

Volume 5.78M

Average 6.04M

ELAN Debt Repayment

Cash used to repay borrowings during the period.

Elanco Animal Health IncorporatedNYSE: ELAN

Debt Repayment · Q3 FY2026 · quarter ended Sep 2026

Debt repayment turns negative

Q3 FY2026 debt repayment was -$215M, compared with $102M a year earlier. Trailing-twelve-month debt repayment was $258M. Over 3 fiscal years it compounded at +2.9% a year.

Context

  • Debt repayment amounted to 11.9% of revenue in FY2025, down 21.3 pp from a year earlier.
  • Debt repayment grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly debt repayment holds near -$215M or moves back toward the trailing-twelve-month quarterly average of $64.5M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$215M+194.5% QoQ
Last fiscal yearDec 2025
-$563M-61.8% YoY
LTMSep 2026
$258M+183.2% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-310.8%——
1 year-61.8%——
3-year CAGR+2.9%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(563M) USD
Year-over-year change
+61.8%

Debt Repayment vs competitors

How ELAN compares with its peers on the latest reported figures

  • ELAN's LTM Sep 2026 debt repayment of $258M is the 3rd largest of the 6 companies compared; the peer median is $19.93M.
  • Its year-over-year change of +183.2% is the 2nd highest of 5, against a peer median of -127.2%.
  • Debt repayment amounts to 5.0% of revenue for ELAN, versus a peer median of 15.3%.
ELAN Competitors Peer median
Debt Repayment for ELAN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$18.64B +723.0%—28.1%
ZTSZoetis Inc.LTM Jun 2026$2.27B —+18.9%23.8%
ELANElanco Animal Health IncorporatedLTM Sep 2026$258M +183.2%+2.9%5.0%
PAHCPhibro Animal Health CorporationLTM Mar 2026$229.24M -192.0%+79.8%15.3%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$131M -174.2%—2.8%
NEOGNeogen CorporationLTM Aug 2026$19.93M -80.1%+0.0%2.3%
Peer median (excluding ELAN) $19.93M-127.2%+18.9%15.3%

Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(472M)(78M)(1.23B)338M(232M)
Depreciation & Amortization716M682M694M662M680M
Deferred Income Tax(154M)(57M)(80M)(112M)(134M)
Stock-Based Compensation66M59M46M55M68M
Change in Working Capital(87M)(462M)(300M)149M99M
Accounts Receivables(3M)14M(40M)12M(12M)
Inventory27M(269M)(160M)44M(57M)
Accounts Payables(120M)(98M)(94M)82M147M
Other Working Capital9M(109M)(6M)11M21M
Other Non-Cash Items414M308M1.14B(551M)79M
Operating Cash Flow483M452M271M541M560M
Capital Expenditures(197M)(184M)(154M)(147M)(276M)
Acquisitions (Net)(342M)13M(19M)1.32B0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities9M(8M)(10M)(14M)(3M)
Investing Cash Flow(530M)(179M)(169M)1.16B(279M)
Debt Repayment177M(517M)(77M)(1.48B)(563M)
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities33M(32M)(6M)(17M)288M
Financing Cash Flow210M(549M)(83M)(1.49B)(275M)
Effect of Forex Changes(31M)(17M)(12M)(91M)71M
Net Change in Cash132M(293M)7M116M77M
Free Cash Flow286M268M117M394M284M

Elanco Animal Health Incorporated

NYSE:ELAN

Intrinsic Alpha fair value

Locked

Current Price

$26.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.